JP2023520330A - 結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤 - Google Patents

結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤 Download PDF

Info

Publication number
JP2023520330A
JP2023520330A JP2022557840A JP2022557840A JP2023520330A JP 2023520330 A JP2023520330 A JP 2023520330A JP 2022557840 A JP2022557840 A JP 2022557840A JP 2022557840 A JP2022557840 A JP 2022557840A JP 2023520330 A JP2023520330 A JP 2023520330A
Authority
JP
Japan
Prior art keywords
chd1l
groups
group
alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520330A5 (https=
Inventor
ダニエル ブイ． ラバーベラ，
ジョシュア エム． アボット，
チオン チョウ，
アデドイン ディー． アブラハム，
ヘクター エスカー，
ブレット ジョセフ プリガロ，
Original Assignee
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト filed Critical ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト
Publication of JP2023520330A publication Critical patent/JP2023520330A/ja
Publication of JP2023520330A5 publication Critical patent/JP2023520330A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022557840A 2020-03-24 2021-03-24 結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤 Pending JP2023520330A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994259P 2020-03-24 2020-03-24
US62/994,259 2020-03-24
US202163139394P 2021-01-20 2021-01-20
US63/139,394 2021-01-20
PCT/US2021/023981 WO2021195279A2 (en) 2020-03-24 2021-03-24 Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer

Publications (2)

Publication Number Publication Date
JP2023520330A true JP2023520330A (ja) 2023-05-17
JP2023520330A5 JP2023520330A5 (https=) 2024-04-04

Family

ID=77892666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557840A Pending JP2023520330A (ja) 2020-03-24 2021-03-24 結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤

Country Status (6)

Country Link
EP (1) EP4127209A4 (https=)
JP (1) JP2023520330A (https=)
CN (1) CN115667553A (https=)
AU (1) AU2021244209A1 (https=)
CA (1) CA3172987A1 (https=)
WO (1) WO2021195279A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222727A1 (en) * 2021-06-17 2022-12-22 The Regents Of The University Of California E3 ligase inhibitors and methods of use thereof
WO2023055763A2 (en) * 2021-09-30 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer
CN114457007B (zh) * 2022-02-28 2024-05-28 合肥燃音生物科技有限公司 一种基于微孔板的均一的单类器官模型及其制备方法
CA3250274A1 (en) * 2022-05-02 2023-11-09 Eisbach Bio Gmbh USE OF ALC1 INHIBITORS AND SYNERGY WITH PARPI
CN115290774B (zh) * 2022-07-21 2023-07-21 重庆医科大学 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用
WO2024211314A2 (en) * 2023-04-03 2024-10-10 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of chd1l and uses thereof
WO2025088087A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
AU2024366320A1 (en) * 2023-10-25 2026-04-16 Eisbach Bio Gmbh Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
WO2025093706A1 (en) * 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan
WO2025129032A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Chd1l inhibitors for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761909A (zh) * 2019-01-25 2019-05-17 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
CN102792160B (zh) * 2010-01-08 2015-08-19 新加坡科技研究局 用于治疗癌症的方法和组合物
US20140243403A1 (en) * 2011-06-03 2014-08-28 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
BR112015003655A2 (pt) * 2012-08-23 2017-07-04 Virostatics Srl composto; uso de um composto; e composição farmacêutica
US20160138114A1 (en) * 2013-06-19 2016-05-19 The Regents Of The University Of California Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761909A (zh) * 2019-01-25 2019-05-17 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOL CANCER THER, vol. vol. 19(8), JPN6025020169, 4 June 2020 (2020-06-04), pages 1598 - 1612, ISSN: 0005599318 *

Also Published As

Publication number Publication date
CN115667553A (zh) 2023-01-31
WO2021195279A3 (en) 2021-11-11
WO2021195279A2 (en) 2021-09-30
AU2021244209A1 (en) 2022-11-03
EP4127209A4 (en) 2024-07-24
CA3172987A1 (en) 2021-09-30
EP4127209A2 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP2023520330A (ja) 結腸直腸がんに対する前臨床活性を有する発がん性ｃｈｄ１ｌの低分子阻害剤
Wang et al. Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast cancer with wild-type BRCA
TWI811358B (zh) ＥｒｂＢ受體抑制劑
Guo et al. Design and synthesis of dual EZH2/BRD4 inhibitors to target solid tumors
JP2021020957A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
US20250101043A1 (en) Kras inhibitors
CN112585119A (zh) 经取代的吲哚及其使用方法
EP4192826A1 (en) Small molecules for the treatment of autoimmune diseases and cancer
WO2022032224A1 (en) Compositions and methods for the treatment and diagnosis of cancer
US20200405707A1 (en) Diazinyl amino acridines and medical uses thereof
Salem et al. Novel 2-substituted-quinoxaline analogs with potential antiproliferative activity against breast cancer: insights into cell cycle arrest, topoisomerase II, and EGFR activity
Wang et al. Discovery of 2-aryl-4-aminoquinazolin-based LSD1 inhibitors to activate immune response in gastric cancer
US20230103444A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
Zhang et al. Discovery of dual CDK6/BRD4 inhibitor inducing apoptosis and increasing the sensitivity of ferroptosis in triple-negative breast cancer
Zhu et al. Discovery of novel 5-cyano-3-phenylindole-based LSD1/HDAC dual inhibitors for colorectal cancer treatment
Zhou et al. Development of novel Indole-Based covalent inhibitors of TEAD as potential antiliver cancer agents
CA2805658C (en) Combination therapy with mdm2 and egfr inhibitors
WO2024211314A2 (en) Inhibitors of chd1l and uses thereof
Oh et al. Discovery of 2, 6-Naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma
JP2024537790A (ja) 癌を処置するための腫瘍形成性ｃｈｄ１ｌの小分子阻害剤
KR102052780B1 (ko) 오로라 및 flt3 키나제 조절자
CN112010789A (zh) 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
HK40087586A (zh) 致癌chd1l的具有抗结肠直肠癌的临床前活性的小分子抑制剂
WO2023025912A1 (en) Use of gcn2 inhibitors in treating cancer
Zhang et al. Discovery of Novel CBP/p300 and BRD4 Dual-Target PROTACs with Potent Antitumor Activity in Prostate Cancer

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230904

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260302